Introduction {#sec1-1}
============

Primary central nervous system tumors (PCNST) are known as all primary tumors which were arise from the main tissue or envelopes of the central nervous system (CNS).\[[@ref1][@ref2][@ref3][@ref4]\] These tumores are categorized into, benign, malignant or uncertain evolution. PCNST indicates a heterogeneous group of tumors, including 143 histological subtypes based on the World Health Organization (WHO) classification.\[[@ref1][@ref2]\] The overall incidence rate of all PCNST showes a range from 17.6/105 to 22.0/105 in American and European literatures.\[[@ref5][@ref6][@ref7][@ref8]\] Because of these tumors are responsible for high mortality and morbidity they are considered as a major public health issue whole over the world.\[[@ref9]\] There is lack of Epidemiological data on PCNST in many countries including Iran because of the lack of a registration system on PCNT. There are numerous difficulties for tumor registries. Since data recording requires collecting all data from a high number of sources: data from neurosurgeons, radiologists, pathologists and death certificates, its time-consuming and not applicable in all facilities.\[[@ref7]\] However, few national registries have provided theese type of information in their database. Among them, the Central Brain Tumor Registry of the United States (CBTRUS) provides valuable data on PCNST, classified based on the histology-grouping scheme.\[[@ref5]\]

Despite the importance of epidemiologic studies on brain tumors, based on what mentioned above, there is a lack of such data in our area as a referral center of the northwest of Iran. Therefore, we decided to collect the epidemiologic data on PCNST based on a 5-year retrospective study.

Primary objective of our study was to provide descriptive epidemiological data of all histologically confirmed subtypes of PCNST in the East Azerbaijan province in Iran. It can provide a pile of valuable information for future epidemiological studies.

Materials and Methods {#sec1-2}
=====================

In this retrospective study, all patients (no age limit) with a histologically proven PCNST hospitalized between April 2011 and March 2016 in Tabriz were included (includes all hospitals of Tabriz University of Medical Science) and variables such as age, sex, and family history were retrospectively collected by referring to the hospital records of patients and entered into the data collection form. All tumors were assorted based on the WHO classification. It should be noted that according to the WHO classification, pituitary tumors do not belong to the PCNST.\[[@ref1]\] However, these types of tumors are included in a few registries, such as the CBTRUS, and in the present study, as well.

Exclusion criteria were considered as secondary tumors of the CNS (metastases) and duplicate records for the recurrent disease of the same patient; in that case, data from the first surgery were recorded if within the inclusion criteria.

The sex ratio and average age of patients at the time of diagnosis were provided for each histological subtype. Data collected from the registered documents of all patients and analyzed with SPSS by using frequency, cumulative frequency, independent sample *t*-test, analysis of variance, Chi-square, and Fisher\'s statistical tests. In this study, *P* \< 0.05 was considered statistically significant.

Patients who had no definitive pathologist diagnosis after mass removal had been excluded from the study.

Ethical consideration {#sec2-1}
---------------------

Patients information entered into this study from archival records of individuals with a codename without mentioning true names of any participants. None of the patients' personal information was included in this research.

Results {#sec1-3}
=======

In this study, 610 patients with a primary diagnosis of brain tumor were examined. After modifying samples based on inclusion and exclusion criteria, there were 373 incident cases of CNS tumors were recorded between 2011 and 2016; among them, 347 was PCNST that includes 92.5% of all CNS tumors. The case distribution according to the tumor type and to prevalence was meningioma (22%), GBM (19.2%), astrocytoma (15.5%), oligodendroglioma (8.5%), metastatic tumors (7.5%), Schwannoma (7%), pituitary adenoma (5.9%), medulloblastoma (4.3%), ependymoma (3.2%), primary brain lymphoma (1.3%), hemangioblastoma (1.3%), papilloma (1.3%), craniopharyngioma (1.1%), primitive neuroectodermal tumor (0.8%), hemangiopericytoma (0.5%), neurocytoma (0.3%), and chondroid chordoma (0.3%) of all.

The tumor distribution according to the histology group is shown in [Table 1](#T1){ref-type="table"} and [Chart 1](#F1){ref-type="fig"}.

###### 

Case distribution according to the tumor type

                                   Sex     Total   
  -------------------------------- ------- ------- -------
  Tumor type                                       
   GBM                                             
    Count                          52      21      73
    Percentage within tumor type   71.2    28.8    100.0
    Percentage within sex          27.7    11.4    19.6
   Astrocytoma                                     
    Count                          34      24      58
    Percentage within tumor type   58.6    41.4    100.0
    Percentage within sex          18.1    13.0    15.5
   Lymphoma                                        
    Count                          3       2       5
    Percentage within tumor type   60.0    40.0    100.0
    Percentage within sex          1.6     1.1     1.3
   Ependymoma                                      
    Count                          5       7       12
    Percentage within tumor type   41.7    58.3    100.0
    Percentage within sex          2.7     3.8     3.2
   Pituitary adenoma                               
    Count                          15      7       22
    Percentage within tumor type   68.2    31.8    100.0
    Percentage within sex          8.0     3.8     5.9
   Meningioma                                      
    Count                          20      62      82
    Percentage within tumor type   24.4    75.6    100.0
    Percentage within sex          10.6    33.5    22.0
   Sechwannoma                                     
    Count                          12      14      26
    Percentage within tumor type   46.2    53.8    100.0
    Percentage within sex          6.4     7.6     7.0
   Craniopharyngioma                               
    Count                          3       1       4
    Percentage within tumor type   75.0    25.0    100.0
    Percentage within sex          1.6     0.5     1.1
   Medulloblastoma                                 
    Count                          7       9       16
    Percentage within tumor type   43.8    56.3    100.0
    Percentage within sex          3.7     4.9     4.3
   Hemangioblastoma                                
    Count                          4       1       5
    Percentage within tumor type   80.0    20.0    100.0
    Percentage within sex          2.1     0.5     1.3
   Metastatic tumor                                
    Count                          15      13      28
    Percentage within tumor type   53.6    46.4    100.0
    Percentage within sex          8.0     7.0     7.5
   Oligodendroglioma                               
    Count                          15      15      30
    Percentage within tumor type   50.0    50.0    100.0
    Percentage within sex          8.0     8.1     8.0
   PNET                                            
    Count                          1       2       3
    Percentage within tumor type   33.3    66.7    100.0
    Percentage within sex          0.5     1.1     0.8
   Papilloma                                       
    Count                          1       4       5
    Percentage within tumor type   20.0    80.0    100.0
    Percentage within sex          0.5     2.2     1.3
   Hemangiopericytoma                              
    Count                          1       1       2
    Percentage within tumor type   50.0    50.0    100.0
    Percentage within sex          0.5     0.5     0.5
   Neurocytoma                                     
    Count                          0       1       1
    Percentage within tumor type   0.0     100.0   100.0
    Percentage within sex          0.0     0.5     0.3
   Chondroid chordoma                              
    Count                          0       1       1
    Percentage within tumor type   0.0     100.0   100.0
    Percentage within sex          0.0     0.5     0.3
   Total                                           
    Count                          188     185     37 3
    Percentage within tumor type   50.4    49.6    100.0
    Percentage within sex          100.0   100.0   100.0

PNET -- Primitive neuroectodermal tumor; GBM -- Glioblastoma multiforme
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According to the WHO Grading of brain tumors in the current study, 47.5% of patients classified as Grade I, 13.3 were in Grade II, Grade III, and Grade IV accounted for 11.9% and 27.2% of cases, respectively.

At the time of diagnosis, 37 (9.6%) patients were aged fewer than 15 years. There was a significant difference in the relationship between types of brain tumors with the age of the patients was found in this study (*P* \< 0.01). Based on that, medulloblastoma was the tumor type that most commonly affected young individuals, and hemangioblastoma was the most common tumors of elderly patients.

The age characteristics of all the cases according to the histological subtype are presented in [Chart 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}.

###### 

Age distribution of cases based on tumor type

  Tumor type           *n*   Mean    SD       Median
  -------------------- ----- ------- -------- --------
  Hemangiopericytoma   2     73.00   19.799   73.00
  Chondroid chordoma   1     70.00   .        70.00
  Metastatic tumor     28    60.29   14.251   59.00
  Meningioma           82    57.10   14.349   58.00
  Pitoitary adenoma    22    53.00   15.185   47.50
  GBM                  73    50.38   17.403   52.00
  Craniopharyngioma    4     49.50   13.528   50.50
  Schwannoma           26    49.00   14.489   48.50
  Oligodendroglioma    30    44.67   16.089   48.50
  Astrocytoma          58    39.78   22.092   41.00
  Lymphoma             5     38.00   22.338   49.00
  Papilloma            5     37.20   30.417   42.00
  PNET                 3     36.33   42.194   14.00
  Hemangioblastoma     5     33.80   5.718    34.00
  Neurocytoma          1     27.00   .        27.00
  Ependymoma           12    16.25   13.712   13.50
  Medulloblastoma      16    15.19   9.005    11.00
  Total                373   47.37   20.288   49.00

PNET -- Primitive neuroectodermal tumor; GBM -- Glioblastoma multiforme; SD -- Standard deviation
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Among the patients, 59.4% were male, corresponding to a ratio male/female of 1.19. The mean age was 52.6 years (51.9 for males and 53.3 for females).

In the present study, the most common brain tumor in male patients is GBM and astrocytoma with a prevalence of 27.7% and 18.1% respectively, and meningioma is the most frequent tumor type of females with a frequency of 33.5%.

Regarding the correlation between gender and tumor type also a meaningful relationship was found (*P* \< 0.01). These findings reveal that hemangioblastoma, craniopharyngioma, and GBM mostly affect male patients and on the other hand papilloma and meningioma are more likely diagnosed in females. In addition, neurocytoma and chondroid chordoma were seen with the frequency of one case in female individuals \[[Table 1](#T1){ref-type="table"} and Charts [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}\].
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Discussion {#sec1-4}
==========

In the current study, from April 2011 to March 2016, 373 cases of CNS tumors were found in Tabriz University of Medical Science healthcare provider centers among them PCNST accounts for 92.5% of all cases. This huge imbalance between primary and metastatic CNS tumors is caused due to choosing of nonsurgical and palliative approaches for metastatic tumors because of the end stage nature of this situation as well as the technical limitation of using routine biopsy for all individuals with CNS masses.

As it has been mentioned earlier astrocytic tumors are the most common form of PCNST, and among them, GBM is the most common type which is account for approximately 25% of all primary CNS neoplasms. Astrocytomas also include 15%--20% of all PCNST.\[[@ref5][@ref10][@ref11]\]

The obtained data of the present study revealed a prevalence rate of 19.6% for GBMs and 15.5% for astrocytomas, that is, close to the international statistics.

Meningiomas include 20% of PCNST and more commonly occurs in the last decades of life and is more commonly involved females.\[[@ref9][@ref10]\] In our study, it has been shown that meningeal tumors account for 22% of PCNST and has a high incidence after the 6^th^ decade of life, and also more common in female individuals as well. The frequency was more than twice greater in females than in males. These results are in favor of other studies performed in Europe and the US.\[[@ref12][@ref13]\]

In addition, many studies count the female gender as a known risk factor for meningioma.\[[@ref14]\]

In other related investigations have been done by researchers around the world a different male: female ratio among CNS tumors was reported, which can be explained by the environmental and racial differences among different ethnic groups.\[[@ref10][@ref11][@ref15]\]

In our study, this proportion was almost equal with a slightly high presentation in male individuals.

Based on the results of the present study, medulloblastoma has the highest frequency rate among children with a median age of 11 years. This finding is similar to reports in the northeast of Iran, which explained that medulloblastoma is at the top list of PCNST incidence in children.\[[@ref16]\]

Based on literature Medduloblastomas are mostly known to occure among pediatric population. Data collected from the SEER database revealed that this type of brain tumor represents a tendency to affect children (9.6 versus 0.54 children and adult respectively per million).\[[@ref17]\]

In compare with a similar study in East Azerbaijan province which was done almost 10 years ago, a noticeable alteration in the pattern of CNS malignancies has seen. Based on the study done by Meshkini *et al.*,\[[@ref18]\] hypophyseal adenomas account for the most common type of PCNS malignancy while in our study GBM was the most common type of malignancy.

Primary brain lymphomas also have shown a greater incidence in the current study as compared to the past. This increase in incidence is important because that very type of CNS malignancies just involved and related with immunodeficiency state.

Conclusion {#sec1-5}
==========

Despite the high frequency of brain neoplasms in Iran, there are a few studies have been performed in order to evaluate the distribution of CNS tumors based on demographic and histopathologic types. The current retrospective study demonstrates important pathologic and epidemiologic features of primary CNS tumors in hospitals of the Tabriz University of Medical Science as the most dominant referral center of north-west of Iran. Therefore, this data can provide a preliminary information for upcoming researches.

In general, we can conclude that the incidence and prevalence rate of more invasive CNS tumors is highly increased in the East-Azerbaijan area in comparison with the past decades.

With the importance of CNS tumors and its influence and effect on health care and social systems, also psychological impression on the patients based on the findings of the current study it is clear that the more invasive types of CNS malignancies are growing. Therefore, the necessity of supplementary studies for determining of potential risk factors and rule of today\'s technology in getting involved with this kind of disease is completely clear.
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